Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2010

View Archived Issues

Nonselective inhibitor pandacostat discovered by chemical phylogenetic analysis of HDACs

Enanta Pharmaceuticals describes new antiviral agents

Merck Frosst claims new prostanoid DP2 receptor antagonists

Roche discovers novel inhibitors of Mdm2/p53 interaction

AEgera Therapeutics discloses new apoptosis inducers

Jerini identifies novel bradykinin B2 receptor ligands

Novartis optimizes lysophospholipid receptor S1P1 agonists

Raloxifene decreases epistaxis in hereditary hemorrhagic telangiectasia / News in Context

Johnson & Johnson reports new HIF prolyl hydroxylase inhibitors

Gaucher's disease patients achieve key therapeutic goals with velaglucerase alfa

Vantia discloses dysmenorrhea candidate VA-111913 at ACS meeting

Ziopharm Oncology begins phase I/II indibulin trial in breast cancer

Cedars-Sinai Medical Center launches two-drug trial in brain tumors

Transdel Pharmaceuticals raises funds for Ketotransdel trial

HRA licences additional rights for Esmya to PregLem for benign gynecological disorders

Ark Therapeutics' EG-01257 reduces tumor growth in preclinical studies

FDA issues complete response letter for ChemGenex's Omapro in CML

MaxCyte and Medinet expand license agreement for cell loading technology

Pervasis begins enrollment in phase I/II trial of PVS-10200 for restenosis prevention

Javelin intends to terminate merger agreement with Myriad following offer from Hospira

New phase II CERE-110 trial in Alzheimer's disease set to begin

Horizon Therapeutics and Nitec merge to form Horizon Pharma

MediGene licenses oHSV development program to Catherex

Gilead initiates phase III clinical Quad program in HIV

Inhibitex's phase II FV-100 trial in shingles continues as planned

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.